|
Australian
researchers report that men treated with luteinizing hormone-releasing
hormone (LHRH) analogues -- manmade compounds that decrease
testosterone as a way of fighting advanced prostate cancer
-- may subsequently suffer from memory impairment.
The researchers
reported that in a study of 82 men with advanced prostate
cancer, men receiving androgen suppression monotherapy performed
worse in two of 12 tests of attention and memory six months
later.
They said
half of the 50 men receiving LHRH analogues or cyproterone
acetate (a steroidal antiandrogen) had a "clinically
significant decline" in one or more cognitive tests.
In contrast,
not one patient in the control group showed a decline in any
test performance, the researchers reported in the journal
BJU International.
"Pharmacological
androgen suppression monotherapy for prostate cancer may be
associated with impaired memory, attention and executive functions,"
the researchers concluded.
Source:
Prostate Cancer
Week of August 18, 2002
|
HOME PAGE
